In this large industry sponsored randomized trial of apixaban (an oral Xa inhibitor) versus enoxaparin in patients post-hip THA, patients were treated for 35 days, and followed up at an additional 60 days for the primary outcome (DVT/PE/Death). Patients in the apixaban group had significantly fewer events than the enoxaparin group (1% versus 4%). Apixaban, similar to rivaroxaban, are both oral Xa inhibitors that are effective in preventing VTE after orthopedic surgeries. However, neither are yet FDA approved in the US, and cost remains to be seen (abstract)
Share This Post
Categories
Related Posts
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Leave A Comment